Technology Innovation Institute (TII) and Burjeel Medical City (BMC) are partnering to develop novel immunotherapy solutions for cancer treatment, focusing on T-cell based therapeutics like CAR-T and TIL therapy. In the first phase, TII will construct a computational platform to identify patient-specific antigens from single-cell transcriptomics data, enabling the design of CAR-T cells. The two-year partnership aims to boost the body's immune system to fight cancer and personalize cancer therapies using TII's technologies. Why it matters: This collaboration signifies the UAE's commitment to advancing cancer care through collaborative research and innovative solutions, potentially establishing the country as a leader in personalized oncology treatments.
KAUST researchers led by Dr. Niveen Khashab have developed thermosensitive liposomes for controlled drug release, particularly in cancer therapies. The liposomes are designed to release drugs only when they reach heated tumor tissue, minimizing systemic side effects. Cholesterol moieties are used as anchors to create a "nail" or "comb" effect, enabling temperature-triggered drug release inside cells. Why it matters: This targeted drug delivery system could significantly improve the efficacy and reduce the toxicity of cancer treatments.
UAE universities, including Khalifa University and Gulf Medical University, are actively leveraging AI tools for cancer research and early detection efforts. Researchers at Khalifa University are developing AI models to enhance early diagnosis and predict treatment responses across various cancers like breast, brain, lung, and prostate. Gulf Medical University also employs AI and machine learning in its research initiatives related to cancer treatment and diagnosis. Why it matters: These initiatives highlight the UAE's commitment to advancing healthcare through artificial intelligence, contributing to global efforts in disease combat and aligning with broader health equity goals.
Dr. Fernando Albarracin from the Technology Innovation Institute has presented a novel microwave applicator design for hyperthermia, potentially useful in cancer treatment. The design combines two flat dielectric graded-index (GRIN) lenses to localize electromagnetic energy within a specific spot in the tissue. This system offers a suitable alternative to conventional antenna-based applicators by considering the interface between free space and human tissue. Why it matters: This research introduces a new approach to hyperthermia treatment that could improve the precision and effectiveness of cancer therapy in the region.
KAUST researchers demonstrated a new flash memory device design using gallium oxide, which can withstand harsh environments. In collaboration with the University of Michigan, KAUST researchers explained a key molecular event for the activation of an enzyme associated with cancer. The Summer 2023 issue of KAUST Discovery is now available. Why it matters: These research achievements highlight KAUST's contributions to advanced materials science and biomedical research, with potential applications in space technology and cancer treatment.
KAUST Associate Professor Jürgen Kosel has been named a distinguished lecturer of the Institute of Electrical and Electronics Engineers (IEEE) Sensors Council for 2020-2022. Kosel's research focuses on sensors and transducers with applications in animal monitoring, precision farming, Formula One racing, and biomedical instruments. His group is also developing magnetic devices for high-density data storage and cancer treatment. Why it matters: This recognition highlights KAUST's contributions to sensor technology and its potential impact on diverse fields, including healthcare in developing regions.
This article discusses the use of artificial intelligence in precision oncology, particularly in understanding individual tumor mechanisms and aiding clinical decision-making. Dr. Xinghua Lu, with extensive experience in medicine and biomedical informatics, will present research on individualized Bayesian causal inference methods for investigating oncogenic mechanisms. These methods aim to provide clinical decision support at the cellular, tumor, and patient levels. Why it matters: AI-driven precision oncology can enable more personalized and effective cancer treatments, improving patient outcomes in the region and globally.